IMPLICITY®, a Paris, France-based leader in remote patient monitoring and cardiac data management solutions, announced that it raised $23 million in Series A funding.
The round was led by new investors: Crédit Mutuel Innovation and Bpifrance. Additional investors for the round include BNP Paribas Development and previous seed investors: Serena, XAnge, and Karista.
The new funding will help speed the international rollout of IMPLICITY's AI-based technology and cardiac data management solutions — enabling healthcare professionals around the world with a more holistic approach to caring for cardiac patients.
Proceeds will be used to: Increase the company's market presence in the US and support expansion into new markets and develop additional medical device software to strengthen the technological leadership of the company.
Company: Implicity Inc.
Round: Series A
Funding Month: April 2022
Lead Investors: Crédit Mutuel Innovation and Bpifrance
Additional Investors: BNP Paribas Development, Serena, XAnge, and Karista
Company Website: https://www.implicity.com/
Software Category: Saas-based Remote monitoring platform
About the Company: IMPLICITY® is a software company that provides a universal cardiac remote monitoring and research platform to clinics and service companies, helping them provide the best remote care to cardiac patients. As a digital Medtech, IMPLICITY® develops AI and knowledge-based algorithms to reduce healthcare professionals' workload and allows them to potentially predict patient health status. The IMPLICITY® platform aggregates normalized and standardized data from all implantable cardiac electronic devices across all major manufacturers. In addition to having an FDA cleared solution and multiple CE markings, IMPLICITY® has been the first private company authorized to access the Health Data Hub*, one of the world's largest patient databases, supporting the development of its AI solutions to improve care for patients with chronic heart failure conditions. IMPLICITY® covers more than 60,000 patients in 100 medical facilities across the United States and Europe.